Recent findings from the REBOOT Trial challenge the long-standing use of beta blockers in patients who have experienced an uncomplicated myocardial infarction with preserved heart function. Traditionally prescribed for over 40 years, beta blockers have been a staple in post-heart attack care. However, the trial’s results, presented at the European Society of Cardiology Congress and published in The New England Journal of Medicine, reveal that these medications may not provide any clinical benefit for this patient group.
Led by Dr. Valentin Fuster at the Mount Sinai Fuster Heart Hospital and Spain’s Centro Nacional de Investigaciones Cardiovasculares (CNIC), the REBOOT study involved 8,505 patients from 109 hospitals in Spain and Italy. Participants were randomly assigned to receive beta blockers or not after hospital discharge, with a follow-up period of nearly four years. The results indicated no significant differences in mortality, recurrent heart attacks, or heart failure hospitalizations between the two groups.
Furthermore, a substudy highlighted increased risks for women treated with beta blockers, who exhibited a higher rate of death, heart attacks, or heart failure hospitalizations compared to their untreated counterparts. This risk was not observed in men.
Dr. Borja Ibáñez, Principal Investigator of the study, emphasized that the findings could reshape clinical guidelines and improve treatment protocols for heart attack patients globally. The REBOOT Trial, conducted without pharmaceutical industry funding, aims to streamline heart attack care, reduce unnecessary side effects, and enhance patient quality of life.
Overall, this research prompts a reevaluation of established treatment practices, suggesting that the benefits of older medications like beta blockers may need to be reconsidered in light of modern advancements in cardiac care.